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Abstract
Plasmodium vivax infections remain a major source of malaria-related morbidity and mortality. Early and accurate diagnosis
is an integral component of effective malaria control programs. Conventional molecular diagnostic methods provide
accurate results but are often resource-intensive, expensive, have a long turnaround time and are beyond the capacity of
most malaria-endemic countries. Our laboratory has recently developed a new platform called RealAmp, which combines
loop-mediated isothermal amplification (LAMP) with a portable tube scanner real-time isothermal instrument for the rapid
detection of malaria parasites. Here we describe new primers for the detection of P. vivax using the RealAmp method. Three
pairs of amplification primers required for this method were derived from a conserved DNA sequence unique to the P. vivax
genome. The amplification was carried out at 64uC using SYBR Green or SYTO-9 intercalating dyes for 90 minutes with the
tube scanner set to collect fluorescence signals at 1-minute intervals. Clinical samples of P. vivax and other human-infecting
malaria parasite species were used to determine the sensitivity and specificity of the primers by comparing with an 18S
ribosomal RNA-based nested PCR as the gold standard. The new set of primers consistently detected laboratory-maintained
isolates of P. vivax from different parts of the world. The primers detected P. vivax in the clinical samples with 94.59%
sensitivity (95% CI: 87.48–98.26%) and 100% specificity (95% CI: 90.40–100%) compared to the gold standard nested-PCR
method. The new primers also proved to be more sensitive than the published species-specific primers specifically
developed for the LAMP method in detecting P. vivax.
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Introduction
Malaria remains one of the top five causes of death in low
income countries and is a major source of morbidity worldwide
[1]. In 2010, the World Health Organization (WHO) estimated
that 216 million clinical cases and 655,000 deaths were due to
malaria infections [2]. Geographically, Plasmodium vivax is the most
widely distributed human-infecting species, with up to 2.6 billion
people at risk for infection [3]. Historically, P. vivax infections have
been viewed as ‘‘benign’’ and self-limiting [4,5]. However, recent
evidence suggests that P. vivax infection causes significant
morbidity including severe illness leading to mortality [5–7]. P.
vivax can also co-occur with other Plasmodium species causing
further complications for accurate diagnosis and treatment [8].
Early and accurate diagnosis of malaria is essential for case
management and for malaria control programs [9]. Current
diagnostic methods include microscopy, immunochromatographic
rapid diagnostic tests (RDTs) that target parasite proteins, and
polymerase chain reaction (PCR) -based molecular tests. Each
method has advantages and limitations. Microscopy is considered
the gold standard of malaria diagnosis in endemic countries.
Correctly employed, it can identify different species and quantitate
infection levels. While inexpensive, microscopy is time-consuming,
labor-intensive, and it requires well-trained personnel along with
appropriate infrastructure [10]. RDTs are easy to use, provide
quick results, and are useful alternatives when there is no access to
microscopic diagnosis [11]. One major limitation is that most
RDTs cannot readily distinguish P. vivax from other species.
Molecular diagnostic techniques based on DNA amplification such
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as PCR-based assays (standard, nested, and real-time) are highly
sensitive and retain the ability to accurately differentiate between
species [10]. However, since these methods require technical
expertise, a well-equipped laboratory, and have long turnaround
times, they are beyond the capacity of most malaria-endemic
countries, making them difficult to implement in simple clinical
laboratories or field settings.
The loop-mediated isothermal amplification (LAMP) method
shows great potential for field use as it is simple and field-amenable
[12]. DNA is amplified under isothermal conditions, removing the
need for sophisticated and expensive thermal cyclers. LAMP
employs autocycling strand displacement DNA synthesis using
Bacillus stearothermophilus (Bst) DNA polymerase and a set of four
primers that bind to unique sites on the target sequence making
them highly specific [12]. The use of two loop primers shortens the
time to product formation, thereby reducing overall reaction time
to between 30 minutes and an hour [13]. LAMP has been utilized
to detect malaria parasites mainly using the conventional 18S
ribosomal RNA (18S rRNA) gene as the target sequence [14–18].
Recently, our laboratory developed a simple portable device
that integrates the isothermal amplification technique (LAMP)
with a fluorescent detection unit. This new platform, capable of
real-time data collection, is referred to as RealAmp. It was used to
successfully detect malaria parasites using published Plasmodium
genus-specific primers [19]. In this study, we have successfully
developed and tested novel P. vivax-specific LAMP primers on the
RealAmp platform. These primers target dispersed genomic
repeats in the P. vivax genome. Repeats were identified using
recently developed diagnostic target mining methods [20].
Methods
Ethics Statement
Clinical samples were retrospectively used in this investigation
that were obtained from a molecular surveillance study conducted
in Venezuela. This study was originally approved by the
institutional ethical review board of Instituto de Altos Estudios
Dr. Arnoldo Gabaldon, Maracay, Aragua State, Venezuela. A
written consent was obtained from the participants. Some of the
clinical samples were obtained from a malaria reference laboratory
in the Centers for Disease Control and Prevention (CDC).
Plasmodium clinical samples and laboratory isolates
We used laboratory-adapted malaria parasites and clinical
samples obtained from two different sources to test the novel
primers. The P. falciparum (3D7) isolate, and other human malaria
Figure 1. Amplification plots for P. vivax strains from different geographic locations using the r64 primer set with SYBR green (A)
and SYTO-9 (B). Amplification plots from P. vivax strains from Pakchong, Chesson and Panama are not shown. Amplification of the template DNA
measured in millivolts (mV) on y-axis over time on x-axis. Any amplification observed after 60 minutes of test time was considered negative. A known
P. vivax DNA sample was used as the positive control. NTC; No Template Control.
doi:10.1371/journal.pone.0054986.g001
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parasites used in this study such as P. vivax, P. malariae, P. ovale and
P. knowlesi were available in the CDC malaria branch collection.
Thirteen geographically diverse P. vivax strains (Miami, El
Salvador, Honduras, Mauritania, Indonesia, India, South Viet-
nam, North Korea, Thailand, New Guinea, Panama, Chesson,
and Pakchong) were included. Due to genetic similarity between P.
vivax and some simian malaria parasites, we also tested eight
simian malaria parasites, P. simiovale, P. inui, P. coatneyi, P. hylobati, P.
fragile, P. gonderi, P. fieldi, and P. cynomolgi. To determine the limits of
detection, we used two fold-serial dilutions of two P. vivax strains
(Brazil and India) starting from 2000 parasites/ml to 0.98
parasites/ml. Sixty eight P. vivax clinical samples were obtained
from a previous surveillance study conducted in Venezuela. In
addition, DNA from 52 clinical samples from our reference
diagnostic laboratory, previously diagnosed using a nested-PCR
method (10 malaria-negative samples, 14 P. falciparum, 9 P. vivax, 1
P. malariae, 12 P. ovale, 2 P. falciparum/P. malariae, 1 P.vivax/P.ovale, 2
P. falciparum/P. ovale mixed infections and 1 P. knowlesi), were
included to test for specificity and sensitivity.
DNA extraction
DNA from blood samples was extracted using the QIAamp
DNA minikit (Qiagen, Valencia CA) according to the manufac-
turer’s recommendations. All extracted samples were aliquoted
and stored at 220uC.
Nested PCR
Nested PCR designed to amplify 18S ribosomal RNA gene
sequences was performed as previously described [19,21]. Briefly,
20 ml amplification reactions containing 1X buffer, 2.5 mM
MgCl2, 200 mM dNTPs, 200 nM primers, and 1.25 units of
Taq Polymerase (New England Biolabs, Ipswich, MA) were
performed on all samples. Nested-PCR products were analyzed via
gel electrophoresis (2% gel) in order to visualize and size the
bands.
Data harvesting
Demas et al. applied highly specific criteria to screen and
identify unique target sequences for P. vivax and P. falciparum
through genome sequence data mining [20]. We used two
previously identified P. vivax sequences (Pvr47 and Pvr64) to
design novel P. vivax-specific LAMP primers. Several potential P.
vivax primers were designed using Eiken’s PrimerExplorer software
v3 (http://loopamp.eiken.co.jp/e/lamp/primer.html). Five prim-
er sets were tested on the RealAmp platform at temperatures
ranging from 60uC to 64uC. Primer sets with the shortest
amplification time that correctly amplified P. vivax with no cross-
reactivity with other human-infecting or primate Plasmodium
species were selected for further analysis.
RealAmp Method
The RealAmp method used for this study has been described in
detail [19]. Briefly, the LAMP assays were performed in a 12.5 mL
total volume containing a 2X in-house buffer (40 mM Tris-HCl
pH 8.8, 20 mM KCl, 16 mM MgSO4, 20 mM (NH4)SO4, 0.2%
Tween-20, 0.8 M Betaine, 2.8 mM of dNTPs each), 0.25 mL of
a 1:100 dilution SYBR green, 8 units of Bst DNA polymerase
(New England Biolabs, Ipswich, MA), and 2 ml of template DNA.
Amplifications were carried out at 64uC for 90 minutes using the
ESE-Quant Tube scanner (Qiagen, USA) collecting fluorescence
signals at 1-minute intervals. All samples were run at least twice
using the r64 primer set as well as published P. vivax LAMP
primers [15]. If the two runs were discordant, the sample was run
a third time and a criterion of two concordant results out of three
runs was used to make the final call. We used a cutoff of
60 minutes and any sample that amplified after this cutoff point
was considered to be negative. Since SYBR Green has known
potential inhibitory effects on DNA amplification [22,23], all
samples were also tested using 1:400 dilution of SYTO-9
fluorescent dye.
Table 1. P. vivax r64 RealAmp primer set sequence (59R39).
F3 TCT GTT GGT GGA GTA GAT CC
B3 CCT ACG TTT TGG TGA ATC G
FIP ATA TGG TCT CTC GAC ACG GC – CAA ATT GCC ATC ATC TTC AC
BIP TGT GCC CAC CCA CAT ACT TA – GGG AAA TGT TAA TGG GGA TGT
LF AGG CTA CTT CTT TTG CTC C
LB ACT TAC AGT GCT GTA GAG A
doi:10.1371/journal.pone.0054986.t001
Table 2. Specificity results of the r64 primer set when tested
against human-infecting and simian-infecting malaria
parasites.
Human and simian malaria














Malaria-negative human DNA 2
All species were tested at least twice for reproducibility.
doi:10.1371/journal.pone.0054986.t002
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Statistical Analysis
A total of 120 and 118 samples were included in the sensitivity
and specificity analyses of the novel Pvr64 and published P. vivax
primers [15], respectively. Nested PCR as described by Singh et al.
provided a gold standard [21]. Specificity and sensitivity were
calculated as follows:
Sensitivity = true positives/(true positives + false negatives) X 100.
Specificity = true negatives/(true negatives + false positives) X 100.
95% confidence intervals (95% CI) were also calculated.
Results
Novel candidates for primer design
The Pvr47 sequence is described in Demas et al [20]. Pvr64 is
a highly conserved repeat family (.98% identity) present in six
copies in the P. vivax genome. Five copies are on small contigs that
were not assembled into chromosome scaffolds because of their
repetitive nature [24]. The remaining copy is on chromosome 9,
,500 kb from the end of the assembly. Three of the copies are
located inside the annotated proteins PVX_092555,
PVX_246295, and PVX_238290. PVX_092555 is Plasmodium-
specific and has orthologs in the human-infecting species P.
falciparum and P. knowlesi, as well as the rodent-infecting species P.
berghei, P. chabaudi, and P. yoelli. PlasmoDB does not contain
orthologs for PVX_246295 or PVX_238290 [25], but both appear
to be truncated paralogs of PVX_092555 based on their nearly
identical sequences.
The Pvr64 family is contained within the WD40 domain of P.
vivax proteins and most of its Plasmodium orthologs. WD40 domains
are found in many proteins implicated in a variety of functions
across eukaryotes, including signal transduction, transcriptional
regulation, and cell-cycle control. Annotations for most
PVX_092555 orthologs contain little functional information, other
than to note that they are conserved across the genus Plasmodium.
One P. yoelli ortholog is thought to be a transcription factor-
associated protein, while another P. yoelli ortholog (which has very
low sequence similarity to PVX_092555 and does not contain
a WD40 domain) is annotated as an erythrocyte membrane
protein.
The Pvr64 family has a high degree of identity with its
Plasmodium orthologs (nucleotide identity ranges from 68% in P.
falciparum to 86% in P. knowlesi). Because of this high similarity, the
Pvr64 segment used to design the novel primers was aligned with
the P. knowlesi and P. falciparum sequences and the locations of the
six LAMP primers are indicated. Several nucleotide differences
were observed within the region used for the six primers
(Figure S1).
P. vivax primers
Five primer sets were designed from the two selected target
candidates (Pvr64 and Pvr47). Each primer set was first tested with
all known human infecting Plasmodium species. If it was able to
correctly amplify P. vivax and no other species, then we evaluated it
on geographically diverse strains. Based on these criteria, only one
primer set based on the Pvr64 target (r64) was selected for further
validation (Table 1). The other four primers did not give consistent
amplification of the P. vivax DNA and resulted in either very late
amplification or negative results, implying that these were not
good enough.
We found that HPLC purification of the primers provided
better amplification plots with reduced background noise (data not
shown). The time to amplification for all samples tested ranged
from 18 to 49 minutes from the start of the reaction (Figure 1).
Specificity of P. vivax specific LAMP primers
We tested the novel primer sets on all known human malaria
parasites (P. vivax, P. falciparum, P. malariae, P. ovale, and P. knowlesi).
Only P. vivax was amplified (Table 2). In addition, no cross
reactivity was observed with any of the tested simian malaria
parasite species or with the malaria-negative human DNA control
(Table 2).
In order to validate the specificity of primer set r64, P. vivax
strains from different geographic regions (Miami, El Salvador,
Honduras, Mauritania, Indonesia, India, South Vietnam, North
Korea, Thailand, New Guinea, Panama, Chesson, and Pakchong)
were tested. We were able to amplify all of the different strains
using our standard protocol (Figure 1 and data not shown).
Limits of detection, sensitivity and specificity of LAMP
primers in clinical samples
Using serial dilutions of two P. vivax strains from Brazil and
India, the limit of detection of r64 primer set was determined to be
125 parasites/ml and the limit of detection of previously published
Table 3. Sensitivity and specificity among clinical sample of r64 primer set and published P. vivax LAMP primers.
Nested PCR (n) Pvr64
Positive Negative
Positive (74) 70 4
Negative (46) 0 46
Sensitivity 94.59% (95% CI: 87.48–98.26%)
Specificity 100% (95% CI: 90.40–100%)
Nested PCR (n) Han et al. P. vivax LAMP primers [15]
Positive Negative
Positive (72) 26 46
Negative (46) 0 46
Sensitivity 36.11% (95% CI: 25.37–48.35%)
Specificity 100% (95% CI: 90.40–100%)
Nested PCR using published 18S rRNA primers was used as the gold standard. All samples were tested at least twice for reproducibility.
doi:10.1371/journal.pone.0054986.t003
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P. vivax LAMP primers (Han et al.) was determined to be between
250–500 parasites/ml. Clinical samples were used to determine
primer sensitivity and specificity. The r64 primer set accurately
detected 70/74 P. vivax-positive samples. No amplification was
observed with 46 P. vivax-negative samples. Compared to a nested
PCR reference, r64 sensitivity and specificity are 94.59% (95% CI:
87.48–98.26%) and 100% (95% CI: 90.40–100%) respectively
(Table 3). This is a drastic improvement over the sensitivity of
previously published P. vivax LAMP primers (36.11% (95% CI:
25.37–48.35%) with a specificity of 100% (95% CI: 90.40–100%))
in our hands.
SYBR Green versus SYTO-9
The specificity and sensitivity of the P. vivax r64 assay with
SYTO-9 fluorescent dye was found to be the same as that of the
assay with SYBR Green. In addition, the SYTO-9 amplification
plots had lower background noise and in some cases, a better
distinction from baseline fluorescence than the SYBR Green
assays (Figure 1).
Discussion
Though the global distribution and disease burden of P. vivax is
considerable, current molecular diagnostic methods that accurate-
ly detect P. vivax are limited. The RealAmp platform is a potential
tool for using molecular diagnostic techniques in the field. The
assay is simple, and provides rapid results through real-time data
collection. This combination is ideal for developing countries that
may not have the capacity and infrastructure to maintain PCR-
based assays at every health care facility. The objective of this
study was to design and test the utility of a novel set of LAMP P.
vivax-specific primers using different target DNA sequences. The
previously described genome sequence data-mining methods [20],
adapted in this study, have proved to be useful in designing novel
specific primers for P. vivax detection. Recent studies have
developed new P. falciparum diagnostic LAMP primers based on
mitochondrial DNA [26] and the apical membrane antigen-1
(AMA-1) gene sequence [27] was used to amplify P. knowlesi DNA.
These new targets will help optimize the RealAmp assay for
accurate detection of all malaria parasite species.
We have noted previously that Plasmodium subtelomeric regions
harbor repetitive regions that are well suited to species-specific
diagnostic targets [20,28]. As the majority of Pvr64 copies are not
assembled onto chromosomes, and the short assemblies containing
these copies do not contain telltale signs of subtelomeric regions
such as vir genes, we cannot be certain whether or not Pvr64 is
a subtelomeric repeat. However, one chromosomal copy does
occur , 500 kb interior to the end of the assembly, arguably
outside of the nebulously defined ‘‘subtelomeric’’ region. Though
Pvr64 has some overlapping regions in other Plasmodium parasites
such as P. falciparum and P. knowlesi, the primers developed in this
study did not show any cross reactivity with other examined
malaria parasites. While Pvr64 is similar to the 18S rRNA target in
that it is relatively low-copy and not species-specific, it offers
a superior, more sensitive RealAmp target than the 18S rRNA
gene family, perhaps due to its comparatively high degree of
conservation within the P. vivax genome.
The r64 primer set has shown reasonable sensitivity and
specificity in detecting P. vivax among the clinical isolates used,
accurately detecting 70 out of the 74 positive samples. It is possible
that the four P. vivax samples that this primer set missed had low
parasite density. Unfortunately, we were not able to determine this
since we did not have any parasitemia data for the samples used in
this study. Since P. vivax is genetically similar to several simian
malaria parasites, we also tested the r64 primer set on eight simian
parasites and observed no cross-reactivity. These primers were also
able to amplify 13 P. vivax strains from different geographic
locations. It is therefore likely that this assay will be able to detect
P. vivax strains in malaria-endemic regions around the world.
Attempts to use published P. vivax LAMP primers by Han et al.
in the RealAmp platform failed to yield consistent results, and the
sensitivity was not as high as previously reported [15]. Possible
explanations for this observation is the fact that different nested-
PCR methods were used as the gold standard in calculating the
sensitivity and specificity and that different detection methods
were used in these studies. We also tested another published set of
P. vivax LAMP primers by Tao et al [29]. However, these primers
cross reacted with the other human-infecting Plasmodium species (P.
falciparum, P. ovale and P. malariae), hence were not considered for
further evaluation.
In some studies, SYBR Green was shown to have inhibitory
effects on DNA amplification when used in high concentrations
[22,23]. We did not observe any inhibitory effect with SYBR
Green in our assays. However, we obtained better amplification
plots with SYTO-9 with lower background noise and in some
cases, a better distinction from baseline fluorescence. This suggests
that SYTO-9 is a better dye than SYBR Green for RealAmp
assays and is possibly due to perfect spectral match with the
detector. This is an important component of the assay as it will
reduce misclassification of cases and non-cases by the users in the
field.
One of the limitations of this primer set is its low sensitivity. Our
data suggests that the limit of detection of the r64 primer set is
around 125 parasites/mL when a quantified standard was used.
This level of sensitivity might be sufficient for case management of
malaria but not for the detection of sub-clinical malaria cases
which is important during the pre-elimination phase of malaria.
Efforts are underway to improve these limits of detection to enable
detection of lower parasitemia. However, compared to nested
PCR as a gold standard, this method performed reasonably well
with approximately 95% sensitivity in detecting the clinical
samples in a single assay.
As previously described, the RealAmp assay [19] has several
advantages that make it a good choice for field-based molecular
diagnosis of malaria. However, some hurdles need to be overcome
for the RealAmp assay, and any molecular assay, to be truly field-
usable. For example, a major caveat of molecular assays is the
sample preparation phase; many assays require that the template
DNA is purified and isolated. While the use of boiled whole blood
was shown to give decent results with the RealAmp assay [19],
additional studies are required to further simplify this step. In
addition, the cold chain requirement for reagents used by many
molecular assays needs to be addressed. Studies are underway to
investigate if the RealAmp reagents can be combined into a ‘‘kit’’
which would further simplify the protocol, reduce the number of
steps for the end user, and minimize chances of user-introduced
errors in performing this assay. Lyophilized reagents that can be
reconstituted at a later time would reduce preparation time and
address the issue of reagent storage without a cold chain supply.
In conclusion, this study demonstrates that the P. vivax LAMP
primers developed here have the ability to accurately detect P.
vivax infections on the RealAmp platform. Furthermore, the
previously described genome sequence data-mining methods have
proved to be useful in designing primers not just for conventional
PCR [20] but also for LAMP assays. This technique offers great
potential in identifying novel primer sets for detection of other
Plasmodium species.
Plasmodium vivax RealAmp Assay
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e54986
Supporting Information
Figure S1 Comparison of the three sequences. The Pvr64
segment used to design the novel P. vivax primers was aligned with
the P. knowlesi and P. falciparum sequences. The locations of the six
LAMP primers are underlined (italicized sequences indicate
location of the complementary sequences). Nucleotide differences
found in the P. knowlesi (highlighted in green) and P. falciparum
(highlighted in yellow) are shown.
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